Researchers therefore looked for studies using noradrenergic drugs, often including ADHD drugs such as atomoxetine, methylphenidate and guanfacine, to potentially improve cognitive and/or neuropsychiatric symptoms in people with neurodegenerative diseases. They included a total of 19 randomized trials focused on Alzheimer’s disease and mild cognitive impairment, involving a total of more than 1800 patients.
